Skip to main content
. 2021 Aug 6;29(9):2794–2805. doi: 10.1016/j.ymthe.2021.08.001

Table 1.

The efficacy of COVID-19 vaccines

Group The incidence of COVID-19 infection
Vaccine efficacy (95% CI)
Vaccine group (95% CI) Placebo group (95% CI) VE = 100∗(1–RR) %
Vaccine type

Inactivated vaccine (n = 5,705 versus 5,440) 0.0096 (0.0034– 0.0269) 0.0357 (0.0310– 0.0409) 73.11% (34.23–89.03)
Protein subunit (n = 7,500 versus 7,500) 0.0008 (0.0004– 0.0018) 0.0075 (0.0058– 0.0097) 89.33% (81.44–93.10)
RNA-based vaccine (n = 48,578 versus 48,732) 0.0006 (0.0004– 0.0008) 0.0105 (0.0087– 0.0126) 94.29% (93.65–95.40)
Viral vector (non-replicating; n = 40,285 versus 30,275) 0.0037 (0.0013– 0.0102) 0.0181 (0.0129– 0.0255) 79.56% (60.00–89.92)

Gender

Male (n = 36,245 versus 30,071) 0.0010 (0.0003– 0.0038) 0.0137 (0.0094- 0.0200) 92.70% (81.00–96.81)
Female (n = 29,774 versus 25,955) 0.0018 (0.0006– 0.0054) 0.0148 (0.0098– 0.0223) 87.84% (75.78–93.88)

Age

16 to 55 years old (n = 47,958 versus 39,139) 0.0018 (0.0006– 0.0055) 0.0162 (0.0117– 0.0224) 88.89% (75.45–94.87)
Over 55 years old (n = 19,458 versus 18,390) 0.0013 (0.0005– 0.0038) 0.0105 (0.0067– 0.0164) 87.62% (76.83–92.54)

Race

Black or African American (n = 9,952 versus 9,979) 0.0005 (0.0000– 0.0138) 0.0108 (0.0043– 0.0265) 95.37% (47.92–100.00)
White (n = 35,650 versus 35,719) 0.0016 (0.0004– 0.0063) 0.0157 (0.0104– 0.0234) 89.81% (73.08–96.15)
HHS Vulnerability Disclosure